The BBC reported that AstraZeneca and Pfizer are credited with together saving more than 12 million lives in the first year ...

Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

The findings of a study into the effect of COVID-19 vaccines on children are being misrepresented in posts shared on social ...

New research led by the University of Washington found that wildfire smoke is especially hazardous to people's memory health. An analysis of the health care records of 1.2 million Southern California ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Anthropic is embroiled in a copyright lawsuit alleging its Claude chatbot regurgitates copyrighted, sometimes without being ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

(This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3 ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

In this Q&A, He discussed Boehringer's investments in AI as well as areas where the technology could deliver greater value for pharma.

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...